March 1, 2024
Chugai Pharmaceutical said on February 29 that it has been granted approval in Japan for FoundationOne CDx Cancer Genomic Profile as a companion diagnostic for Eli Lilly’s RET kinase inhibitor Retevmo (selpercatinib) for RET fusion-positive solid tumors. Lilly is currently...read more